Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Glioblastoma 7Multiple Myeloma 6Lymphoma, B-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Follicular 5Leukemia, Lymphocytic, Chronic, B-Cell 5Recurrence 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Burkitt Lymphoma 4Prostatic Neoplasms 3Lymphoma, Non-Hodgkin 3Glioma 3Astrocytoma 3Sarcoma 2Melanoma 2Lymphoma 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Metastatic Hormone-Sensitive Prostate Cancer 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

Docetaxel 43enzalutamide 31Prednisone 25Abiraterone Acetate 24Magnetic Resonance Spectroscopy 18abiraterone 15pembrolizumab 14bicalutamide 14Radiotherapy 14Cyclophosphamide 13darolutamide 12Leuprolide 12Goserelin 12apalutamide 10Ipilimumab 10olaparib 9Specimen Handling 9Radiosurgery 9Radiation 9Injections 9Biopsy 9Pluvicto 8Paclitaxel 8Radiotherapy, Intensity-Modulated 7Carboplatin 7sargramostim 6fludarabine 6cabazitaxel 6Sirolimus 6Nivolumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms × Leukapheresis × Clear all
NCT07219147 2026-04-20

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

City of Hope Medical Center

Phase 1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT05805371 2025-11-19

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

City of Hope Medical Center

Phase 1 Recruiting
21 enrolled
Genitourinary

Prostatic Neoplasms

NCT06094842 2025-04-01

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Fred Hutchinson Cancer Center

Phase 1 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡